Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Andrada-Luciana Lazar4th Medical Clinic, Internal Medicine Department, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.ORCID 0000-0001-8428-8088
Sorana D BolboacăMedical Informatics and Biostatistics, Department 11-Medical Education, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, 400349 Cluj-Napoca, Cluj, Romania.ORCID 0000-0002-2342-4311
Adrian-Lucian BaicanDepartment of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.
Corina-Iulia BaicanDepartment of Dermatology, County Emergency Hospital, 400535 Cluj-Napoca, Cluj, Romania.
Sorina DănescuDepartment of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.ORCID 0000-0003-0968-4026
Elisabeta CandreaDepartment of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.
Adela-Viviana Sitar-Tăut4th Medical Clinic, Internal Medicine Department, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.ORCID 0000-0001-8590-4583
Romana VulturarDepartment of Cell and Molecular Biology, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400349 Cluj-Napoca, Cluj, Romania.ORCID 0000-0003-2476-9706
Olga Hilda Orășan4th Medical Clinic, Internal Medicine Department, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.
Angela Cozma4th Medical Clinic, Internal Medicine Department, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania.ORCID 0000-0002-3989-2291
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biological TherapyPsoriasisAdalimumabAdolescentAdultAgedAntibodies, Monoclonal, HumanizedBiological ProductsChildChild, PreschoolFemaleHumansInfliximabInterleukin-17Interleukin-23MaleAdalimumabAntibodies, Monoclonal, HumanizedBiological ProductsInfliximabInterleukin-17Interleukin-23Tumor Necrosis Factor-alphaAnti-Interleukin 17 biological therapy (anti-IL-17)Anti-Interleukin 23 biological therapy (anti-IL-23)Anti-Tumor Necrosis Factor biological therapy (anti-TNF)Dermatology Life Quality Index (DLQI)psoriasisPsoriasis Area Severity Index (PASI)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.